Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2000-01-03
2002-02-19
Priebe, Scott D. (Department: 1632)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S023100, C536S023500, C536S023400, C536S024300, C536S024310
Reexamination Certificate
active
06348585
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
SUMMARY OF THE INVENTION
The present invention relates to Human Urotensin II, in particular Human Urotensin II polypeptides and Human Urotensin II polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of acute heart failure; hypotension; hypertension; angina pectoris; myocardial infarction; ulcers; psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with Human Urotensin II imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate Human Urotensin II activity or levels.
REFERENCES:
patent: 6075137 (2000-06-01), Culp et al.
patent: WO 97/49386 (1997-12-01), None
GenBank Accession #AA535545, National Library of Medicine, Bethesda, MD., Aug. 21, 1997.
GenBank Accession #Z98884, National Library of Medicine, Bethesda, MD., Oct. 29, 1997.
Conlon et al. “Somatostatin-and urotensin II-related peptides molecular diversity and evolutionary perspectives”, Regulatory Peptides, vol. 69, pp. 95-103 (1997).
McMaster et al. “Characterization of the Biologically and Antigenically Important Regions of Urotensin II ”, Proceedings of the Western Pharmacology Society, vol. 29, pp. 205-208 (1986).
Perkins et al. “Molecular modelling and design of analogues of the peptide hormone urotensin II ”, Biochemical Society Transactions, vol. 18, pp. 918-919 (1990).
Conlon et al. Distribution and Molecular Forms of Urotensin II and Its Role in Cardiovascular Regulation in Vertebrates, The Journal of Experimental Zoology, vol. 275, pp. 226-238 (1996).
Itoh et al. “Functional receptors for fish neuropeptide urotensin II in major rat arteries”, European Journal of Pharmacology, vol. 149, pp. 61-66 (1988).
Coulouarn et al “Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord”, Proceedings of the National Academy of Sciences of the U.S.A., vol. 95, pp. 15803-15808 (1998).
Culp Jeffrey
Ellis Catherine E
McNulty Dean E
Han William T.
King William T.
Priebe Scott D.
Ratner & Prestia
SmithKline Beecham Corporation
LandOfFree
Human urotensin II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Human urotensin II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Human urotensin II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2961579